Our results suggest that TfR1 protein in either the primary tumor or benign kidney may provide a novel biomarker for nephrectomy patients with prognostic value independent of primary tumor pathology, particularly for ccRCC patients. This evidence concerns the gene TFRC and nonpapillary renal cell carcinoma.